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The selective elimination of subpopulations of cells on the basis of their capacity to 
specifically bind various toxin conjugates has been the focus of recent intensive interest 
and study (1,  2).  The regulatory mechanisms that control the specificity and size of 
discrete B lymphocyte clones occasionally break down and results in the production 
of deleterious antibodies directed against self determinants.  In such cases, it would be 
desirable to suppress specific B cell clones without inhibiting the normal functions of 
the  remainder of the  immune system. Using  an  in  vitro model  system of antigen- 
specific antibody synthesis (3, 4) and an antigen-toxin conjugate, we demonstrate that 
selective abrogation of antigen-specific human B cell responses can be achieved. 
The rationale for the procedure of using a toxin-conjugate to reduce the population 
of specific cells has been previously outlined  (1).  Toxins such as ricin and diphtheria 
consist of two chains, each having different functions (5, 6). The A chain is an enzyme 
capable of inactivating  protein  synthesis once  it  is  transported  to the cytosol com- 
partment. The B chain initiates the entry process by binding the toxin to cell surface 
receptors present  on most cell types.  By replacing the normal toxin  B  chain with  a 
new  binding  chain  having receptor specificity for a  distinct  cell  type,  a  structural 
analogue of the toxin is created (1).  The specificity of cell killing is now determined 
by the new binding chain.  A  variety of such toxin analogues have been constructed 
with varying degrees of potency and cell type specificity (7, 8). 
The antigen-toxin conjugate used in these studies is a thioether conjugate of tetanus 
toxoid (TT) and intact ricin containing both the A and B chains. This was done for 
the initial studies because of recent evidence showing that the toxin-binding B chain 
plays a  role in facilitating A chain entry (9).  This role appears to be independent  of 
surface membrane receptor binding  (2,  10).  Certain  conjugates  containing  toxin  B 
chains have been shown to have faster rates of specific cell killing (2, 9). Conjugates 
of ricin containing the B chain are used in the presence of lactose, which largely (20- 
200-fold)  blocks the ricin entry route via its receptor and thereby reduces nontarget 
cell killing (9). Conjugates constructed along these lines, such as mannose-6-PO4-ricin 
and  monoclonal  anti-Thy-l.2-ricin,  have been  useful  in  selecting  mutant  cell  lines 
deficient  in  mannose-6-PO4  receptors  (11)  and  in  eliminating T  cells  from murine 
bone marrow allografts as a  means of preventing experimental graft-vs.-host disease 
(12), respectively. In both of these cases, the selectivity of the conjugate between target 
and  nontarget  cells  is  between  100:1  and  1000:1,  and  the  desired  objective  is 
achievable without complete elimination of the target cell population  (11,  12). 
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B  lymphocytes have  surface  immunoglobulin (Ig)  that  specifically binds to  the 
antigenic determinant (Ag) against which the B cell is capable of producing antibody. 
This Ag-specific surface  antibody represents a  sensitive Ag-recognition mechanism 
and confers a  high  degree  of specificity and affinity to  the  binding of Ag by Ag- 
specific B  cells,  thus  providing a  potential method  for  the  selective elimination of 
these specific B cells via an Ag-ricin conjugate, while leaving intact the remainder of 
the B cell repertoire. 
Materials and Methods 
Immunization.  Normal subjects, aged 18-25 yr, received a standard booster dose of 5 Lfunits 
of tetanus toxoid intramuscularly (Wyeth Laboratories, Marietta, PA). Certain subjects had 
also been previously immunized with two subcutaneous injections of 5 mg of keyhole limpet 
hemocyanin (KLH) spaced 2 wk apart. 
Cell Separations.  Human peripheral blood mononuclear cells  (PBMC) were obtained from 
either heparinized whole blood or buffy coat fractions by sedimentation over Ficoll-Hypaque 
gradients in a  standard fashion  (13). In certain experiments where  indicated, T  cells  were 
removed from these mononuclear cell fractions by treatment with the anti-T cell monoclonal 
antibody Leu-1  (Becton, Dickinson & Co., Oxnard, CA) and rabbit complement (Dutchland 
Laboratories, Inc., Denver, PA) for 1 h at 37°C, as previously described (4). 
Antigens.  "IT for use in vitro was generously provided by Lederle Laboratories, Pearl River, 
NY. The toxoid was further purified by chromatography on Sephacryl S-200 (Pharmacia Fine 
Chemicals, Div. of Pharmacia Inc., Piscataway, N  J)  into a  homogenous molecular weight 
fraction of 150,000. The antigenicity of this material was identical to that of the crude toxoid 
as determined by an enzyme-linked immunosorbent assay  (ELISA) (3). 
Conjugate Synthesis.  Thiolated tetanus toxoid  was  conjugated with  ricin via  a  thioether 
linkage. To 5 mg of purified toxoid in 1 ml of buffer, 0.1  M  NaPI, pH 7.2, 100/~g of 20 mM 
N-succinimidyl-3(2-pyridyldithio)-propionate  (SPDP) in ethanol was added with stirring. After 
30 min at 25°C, 75 mg of dithiothreitol was added. The thiolated toxoid was freed of reducing 
agent by running  over a  1.8- x 15-cm Sephadex G25F column in the same buffer. Ricin D, 3.5 
mg in 0.2 ml isolated and derivatized with m-maleimidobenzoyl-N-hydroxysuccinimide  ester 
(MBS),  as previously described (14), was added to the peak fraction of the thiolated toxoid. 
After 3 h, the reaction was terminated by adding 50 pl of 1 M N-ethylmaleimide. The reaction 
mixture was  chromatographed  at  1 ml/min in  the  above  buffer  by  high-pressure  liquid 
chromatography on a  7.5- x 600-mm SW TSK 3000 column. A peak at  12.5 ml was observed 
as well as unreacted ricin at  19 ml. Thiolated toxoid ran at  13.5 ml. Fractions 8-14.5 ml were 
pooled, applied to a  2-ml Sepharose 4B  column at  4°C. Washing with phosphate-buffered 
saline (PBS)  removed unreacted tetanus toxoid, while ricin conjugate remained bound. The 
conjugate was eluted as a sharp peak with 100 mM lactose in PBS. 
Culture Conditions.  Cells were preincubated with various combinations of TT, ricin, and/or 
TT-ricin  conjugates for 2 h at 37°C in RPMI 1640 (Gibco Laboratories, Grand Island Biological 
Co.,  Grand Island, NY)  containing 100 mM lactose to inhibit binding of ricin to nontarget 
cells. Preincubation was performed at a cell density of 1-2 ×  10  n cells in 3 ml of medium. Cells 
were then washed once with a 25 mM lactose RPMI  1640 solution and then twice more with 
RPMI  1640 alone. After preincubation, cells were cultured in  12- x  75-ram round-bottomed 
tubes at between 5 x  10  ~ and 8 ×  105 cells per tube for  10 d in 1 ml of RPMI 1640 containing 
10% heat-inactivated fetal calf serum, 20 /~g/ml  gentamicin (Schering-Plough Corp., Kenil- 
worth, N  J), and the polyclonal B cell activator pokeweed mitogen (PWM) at a final dilution 
of 1/200 of the stock solution Gibco Laboratories, Grand Island Biological Co.) 
Cultures for measuring blast transformation were  performed as  previously described  (4). 
Cells were stimulated with TT, concanavalin  A (Con A) (Sigma Chemical Co., St. Louis, MO), 
phytohemagglutinin (Burroughs-Wellcome, Beckenham, England), or KLH for 5 d at 37°C in 
5% CO2, then pulsed with 0.4 pCi [3H]thymidine for 4 h, harvested on a Titertek cell harvester 
(Flow Laboratories, Inc., McLean, VA) and counted in a scintillation counter. 
Ig Assays.  Supernatants were assayed for anti-TT IgG, anti-KLH, IgM, and total IgG and 
IgM, as  previously described  (3, 4), using an ELISA system using heavy chain-specific goat 
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Results 
The effect  of preincubation  of PBMC  with TT-ricin  on subsequent  PWM-stimu- 
lated Ig production was examined. Fig.  1 shows a representative experiment in which 
PBMNC were obtained from an individual recently immunized to TT. Preincubation 
with TT alone or with a mixture of TT and ricin had virtually no effect on subsequent 
anti-TT or total Ig production.  However, brief exposure to TT covalently linked to 
ricin  at  concentrations >10  ng/ml  abrogated  anti-TT  synthesis  (P <  0.01)  but  did 
not diminish  total  Ig production.  TT-ricin  also selectively eliminated  anti-TT  anti- 
body  production  without  decreasing  total  Ig  production  in  PBMNC  from  three 
additional TT-immunized individuals.  One of these subjects was immunized to both 
TT  and  KLH.  In  this  case,  preincubation  with  the TT-ricin  conjugate  eliminated 
PWM-induced  anti-TT  production  but  did  not  affect  either  anti-KLH  or total  Ig 
production.  Thus, TT-ricin  selectively removed anti-TT  antibody synthesis but was 
not  toxic  to  B  cells  specific  for  an  unrelated  antigen  (KLH).  Preincubations  were 
performed in the presence of 100 mM lactose to prevent binding of ricin conjugates 
to cells  via  their membrane gatactose  molecules.  Preincubation  with  unconjugated 
ricin  at  up  to  100  ng/ml  under  these conditions  did  not affect  anti-TT  or total  Ig 
production.  When  lactose  was  not  present,  TT-ricin  at  1  ng/ml  inhibited  PWM- 
induced anti-TT antibody synthesis as well as total Ig synthesis by 90%.  Ricin alone 
showed total inhibition of these responses at 0.5 ng/ml  (data not shown). 
The target cell of TT-ricin  action was studied by preincubating T  cell-depleted  B 
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FIo.  1.  Selective abrogation of anti-TI' production in PWM-stimu]ated cultures of PBMC  after 
preincubation with TT-ricin conjugate. Cells were preincubated at various concentrations of either 
TT alone (O), TT plus free ricin (I), or TT-ricin conjugate (O)  for 2 h  at 37°C in the presence of 
100 mM lactose, as described in Materials and Methods. Data are expressed as the geometric mean 
of triplicate determinations of either anti-TT IgG production (A)  or total IgG production (B)  of 
10-d culture supernatants. 0, TT alone; (D, TT-ricin; I,  TT plus ricin. 
Fic.  2.  Selective abrogation of anti-TT production in B  ceils after preincubation with TT-ricin 
conjugate. Unfractionated PBMC (0, O) or B cells (11, F'l) were preincubated with either TT alone 
(0, ID or TT-ricin conjugate (O, rl)  for 2 h at 37°C in the presence of 100 mM lactose. Cultures of 
either 5 X  105 preincubated unfractionated cells or 2 x  10  ~ preincubated B cells plus 5 X  105 fresh 
irradiated unfractionated ceils (1,500 rad)  were incubated for  t0 d, and supernatant anti-TT IgG 
or total IgG were assayed. Data represent the geometric mean of triplicate cultures assayed. 0, UF 
('IT alone); O, UF (TT-riein); I,  B (TT alone); F1, B (TT-ricin). VOLKMAN ET AL.  BRIEF  DEFINITIVE  REPORT  637 
TABLE I 
Effect of TT-ricin  Pretreatment on Subsequent Proliferative Responses of Human Mononuclear Cells 
Pretreatment* 
None 
Subsequent stimulation:~ 
T'T  "IT  Con A  KLH  PHA 
(10 #g/ml)  (20/tg/m[)  (100 ~g/ml)  (20/~g/ml)  (2/~g/ml) 
No antigen  861 §  30,076  38,763  13,404  19,617  20,388 
(± 20)  (+ 2,219)  (± 2,081)  (± 1,198)  (± 2,940)  (± 1,494) 
10 ng "IT  189  29,381  34,289  9,421  19,093  25,441 
(± 20)  (± 4,431)  (- 3,119)  (+ 775)  (4-_ 1,742)  (-  1,223) 
100 ng TT  398  31,450  29,984  10,714  21,224  24,740 
(± 35)  (± 1,8t9)  (± 1,737)  (± 1,039)  (--+ 2,468)  (± 1,282) 
10 ng TT-ricin  384  27,005  39,223  8,368  23,306  20,478 
(± 56)  (± 560)  (± 4,652)  (± 1,020)  (± 4,251)  (± 1,925) 
100 ng TT-ricin  1,623  13,320  14,967  5,973  13,839  21,854 
(± 103)  (± 189)  (+  1,213)  (± 143)  (+ 1,451)  (± 531) 
* PBMNC were preincubated in 100 mM lactose, RPMI  1640 with the designated antigen for 2 h at 37°C, then washed 
as described in Materials and Methods. 
:~ 10  s cells in 200 ml were cultured in round-bottomed microtiter wells for 5 d and then pulsed with 0.4 btCi [3H]thymidine 
for 4 h and harvested. 
§ Data represent mean cpm of triplicate determinations (± SEM). 
cell fractions with either TT alone or TT-ricin conjugate (Fig. 2). After preincubation, 
these  cells  were  reconstituted  with  irradiated  unfractioned  mononuclear  cells,  and 
PWM-induced  Ig synthesis  was  assessed.  Preincubation  with  TT-ricin  eliminated 
anti-TT antibody production in both unfractionated cells and in the B cell fraction 
(P <  0.01),  whereas pretreatment with  unconjugated  TT did  not abrogate anti-TT 
responses. Again, total Ig production was not diminished by TT-ricin pretreatment. 
On  the other hand, pretreatment of PBMC  with TT-ricin did not  abolish T  cell 
blastogenic responses to TT. Table ! shows the results of preincubation of unfraction- 
ated cells with TT alone or TT-ricin in the presence of 100 mM lactose and subsequent 
stimulation. At concentrations of TT-ricin shown to block anti-TT antibody produc- 
tion  (10  ng/ml),  little  effect  on  T  cell  proliferative  responses  to  TT  were  seen. 
Although  100 ng/ml of TT-ricin did decrease the blastogenic response to TT, it also 
decreased responses to Con A  and  KLH (the subject was KLH immunized)  so that 
the effects were not specific for TT-responsive T  cells. 
These  results,  taken  together,  indicate  that  TT-ricin  is  capable  of  selectively 
eliminating TT-specific B cells without significantly affecting the remainder of the B 
cell repertoire or the T  cell population. 
Discussion 
The present study demonstrated that human antigen-specific B cell responses can 
be selectively eliminated by pretreatment in vitro with antigen linked to the cell toxin 
ricin. The remainder of the B cell repertoire, as indicated  by polyclonat Ig responses 
and  antibody  responses  directed  against  other  non-cross-reacting  antigens,  is  pre- 
served.  The  lack  of significant  effect  of TT-ricin  exposure  on  T  cell  proliferative 
responses  to  subsequent  TT  stimulation  as  well  as  the  fact  that  preincubation  of 
purified B cells with TT-ricin selectively abrogated the anti-TT antibody responses of 
these B cells, strongly suggest that TT-ricin conjugates bind directly to the TT-specific 
B cells via their specific surface Ig receptors. 
In the present study, ricin B chain was left attached to the A  chain in making the 
ricin-TT conjugates. The B chain of ricin binds to virtually all mammalian cells via 
glycoprotein galactose residues and also facilitates entry of the toxic A chain into cell 
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cell surfaces (2), preincubations were performed in the presence of 100 mM lactose to 
inhibit binding of the B chain containing complex to nontarget cells. Removal of the 
B chain from the TT-ricin conjugate markedly decreases the nontarget cell toxicity of 
the compound and precludes the necessity of incubation in lactose and thus opens the 
possibility  of in  vivo use  of these  conjugates.  In  this  regard,  preliminary  in  vitro 
studies with TT-ricin A chain conjugates alone have demonstrated similar selective 
abrogation of anti-TT antibody responses (unpublished observations). 
Previous studies (8,  12,  14,  15) demonstrated the feasibility of eliminating popula- 
tions of cells by attaching toxins of various types to antibodies that recognize specific 
antigenic determinants of lymphocyte surfaces. In those studies, the specificity of the 
binding was at  the level of the conjugated antibody directed against  a  cell surface 
determinant  and was  not directly related to the functional capability of the target 
cell. In the present study, the specificity and selectivity of the cytotoxicity is directly 
related to the functional capability of the cell being eliminated, i.e., its surface Ig or 
antigen recognition moiety. There is obvious therapeutic potential in eliminating B 
cells by virtue of their antigen-binding capability in diseases characterized by aberrant 
antibody responses, such as the antibody-mediated autoimmune diseases in which the 
antigen has been identified (16,  t 7). Examples of such diseases include systemic lupus 
erythematosus  nephritis  mediated  by  anti-DNA  antibodies,  Goodpasture's  disease 
mediated  by anti-basement  membrane antibodies,  myasthenia  gravis  mediated  by 
anti-acetycholine receptor antibodies, and several autoimmune endocrine and hema- 
tologic diseases (17). The non-neoplastic nature of these diseases might allow clinically 
relevant suppression of disease activity by such an approach because abrogation of a 
significant proportion but not the entire autoimmune response might be sufficient to 
render the disease subclinical. This has the distinct advantage over the treatment of 
malignant tumors with antibody-toxin conjugates because in animal models complete 
elimination of viable tumor cells must be achieved to prevent recurrences (15). 
Summary 
The feasibility of selectively eliminating human antigen-specific B cell responses by 
treating cells in  vitro with antigen  covalently linked  to a  cell toxin was examined. 
Tetanus  toxoid  (TT)  was  conjugated  to  the  toxin  ricin  via  a  thioether  linkage. 
Peripheral blood mononuclear cells from recently immunized subjects were preincu- 
bated for 2 h with TT-ricin in the presence of lactose. Antigen was then removed, and 
the cells from recently immunized subjects were preincubated for 2 h  with TT-ricin 
in the presence of lactose. Antigen was then removed, and the cells were stimulated 
with  pokeweed mitogen  to induce antibody production.  TT-specific antibody pro- 
duction was completely abrogated by preincubation with TT-ricin but  not  by TT 
alone or a mixture of TT and ricin. In contrast, polyclonal immunoglobulin produc- 
tion was not diminished by TT-ricin. This selective abrogation was also seen when B 
cells alone were preincubated with  TT-ricin and  a  source of T  cell help was  later 
provided. T  cell blastogenic responses to TT remained intact after TT-ricin exposure. 
Thus,  antigen-toxin conjugates are capable  of selectively eliminating  specific anti- 
body-producing  B  cell  clones,  while  leaving  intact  the  remainder  of the  B  cell 
repertoire. 
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